UA116541C2 - Біфтордіоксаланамінобензімідазольні інгібітори кінази для лікування злоякісного новоутворення, аутоімунного запалення і порушень цнс - Google Patents
Біфтордіоксаланамінобензімідазольні інгібітори кінази для лікування злоякісного новоутворення, аутоімунного запалення і порушень цнс Download PDFInfo
- Publication number
- UA116541C2 UA116541C2 UAA201500560A UAA201500560A UA116541C2 UA 116541 C2 UA116541 C2 UA 116541C2 UA A201500560 A UAA201500560 A UA A201500560A UA A201500560 A UAA201500560 A UA A201500560A UA 116541 C2 UA116541 C2 UA 116541C2
- Authority
- UA
- Ukraine
- Prior art keywords
- difluoro
- benzo
- zidioxolo
- carboxamide
- imidazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261664936P | 2012-06-27 | 2012-06-27 | |
| EP12174669 | 2012-07-02 | ||
| PCT/EP2013/063537 WO2014001464A1 (en) | 2012-06-27 | 2013-06-27 | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA116541C2 true UA116541C2 (uk) | 2018-04-10 |
Family
ID=49782305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201500560A UA116541C2 (uk) | 2012-06-27 | 2013-06-27 | Біфтордіоксаланамінобензімідазольні інгібітори кінази для лікування злоякісного новоутворення, аутоімунного запалення і порушень цнс |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9580438B2 (OSRAM) |
| EP (1) | EP2867237A1 (OSRAM) |
| JP (2) | JP6272846B2 (OSRAM) |
| KR (1) | KR102155559B1 (OSRAM) |
| CN (1) | CN104540831B (OSRAM) |
| AU (2) | AU2013283318B2 (OSRAM) |
| BR (1) | BR112014032581A8 (OSRAM) |
| CA (1) | CA2877589C (OSRAM) |
| EA (1) | EA029718B1 (OSRAM) |
| HK (1) | HK1204474A1 (OSRAM) |
| IL (1) | IL236463A0 (OSRAM) |
| IN (1) | IN2014MN02562A (OSRAM) |
| MX (1) | MX350418B (OSRAM) |
| MY (1) | MY167785A (OSRAM) |
| NZ (1) | NZ702618A (OSRAM) |
| SG (1) | SG11201408617PA (OSRAM) |
| UA (1) | UA116541C2 (OSRAM) |
| WO (1) | WO2014001464A1 (OSRAM) |
| ZA (1) | ZA201409194B (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA029718B1 (ru) * | 2012-06-27 | 2018-05-31 | 4-Эс-Си Дискавери Гмбх | Бифтордиоксалан-аминобензимидазольные ингибиторы киназы для лечения рака, аутоиммунного воспаления и нарушений цнс |
| CN106661027B (zh) | 2014-03-20 | 2019-12-24 | 卡佩拉医疗公司 | 苯并咪唑衍生物作为erbb酪氨酸激酶抑制剂用于治疗癌症 |
| KR20240064750A (ko) | 2014-03-20 | 2024-05-13 | 카펠라 테라퓨틱스, 인크. | 암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체 |
| US10112939B2 (en) | 2014-08-21 | 2018-10-30 | Bristol-Myers Squibb Company | Tied-back benzamide derivatives as potent rock inhibitors |
| WO2017013210A1 (en) * | 2015-07-21 | 2017-01-26 | 4Sc Ag | Treatment and prevention of viral diseases with 2,3-dihydrobenzofuran-5-yl compounds |
| WO2017053537A1 (en) | 2015-09-23 | 2017-03-30 | Capella Therapeutics, Inc. | Benzimidazoles for use in the treatment of cancer and inflammatory diseases |
| SMT202200339T1 (it) * | 2016-04-07 | 2022-09-14 | Glaxosmithkline Ip Dev Ltd | Ammidi eterocicliche utili come modulatori di proteine |
| WO2019080898A1 (en) | 2017-10-27 | 2019-05-02 | Shanghai Yao Yuan Biotechnology Co., Ltd. | COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE RESPONSE BY ACTIVATION OF PROTEIN KINASE ALPHA 1 |
| EP3849975A1 (de) | 2018-09-13 | 2021-07-21 | Bayer Aktiengesellschaft | Heterocyclen-derivate als schädlingsbekämpfungsmittel |
| CN109020990A (zh) * | 2018-09-20 | 2018-12-18 | 广西壮族自治区药用植物园 | 苯基苯并呋喃化合物、及其制备方法、组合物和医药用途 |
| EP3643713B1 (en) * | 2018-10-23 | 2025-07-30 | iOmx Therapeutics AG | Heterocyclic kinase inhibitors and uses thereof |
| KR102119150B1 (ko) * | 2018-10-23 | 2020-06-04 | 한국원자력의학원 | N-1h-벤지미다졸-2-일-3-(1h-피롤-1-일) 벤자미드를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물 |
| WO2020132582A1 (en) * | 2018-12-21 | 2020-06-25 | Nimbus Titan, Inc. | Sting agonists and uses thereof |
| CA3184767A1 (en) | 2020-06-26 | 2021-12-30 | Raqualia Pharma Inc. | Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agent |
| CN116942819A (zh) * | 2023-04-24 | 2023-10-27 | 珠海市人民医院 | 微管相关丝氨酸/苏氨酸样激酶抑制剂在制备治疗肿瘤的药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4167569A (en) | 1976-12-09 | 1979-09-11 | Imperial Chemical Industries Limited | Pyrimido[1,2-a ]benzimidazole derivatives |
| US7132438B2 (en) | 2001-10-09 | 2006-11-07 | Amgen Inc. | Benzimidazole derivatives |
| US7338956B2 (en) | 2002-08-07 | 2008-03-04 | Sanofi-Aventis Deutschland Gmbh | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| EP1388341A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| JO2724B1 (en) | 2004-08-19 | 2013-09-15 | افينتس فارماسوتيكالز انك | 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors |
| WO2006130673A1 (en) * | 2005-05-31 | 2006-12-07 | Janssen Pharmaceutica, N.V. | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
| ES2432361T3 (es) | 2005-12-02 | 2013-12-03 | Bayer Healthcare, Llc | Derivados de pirrolotriazina útiles para el tratamiento de cáncer por inhibición de cinasa Aurora |
| PE20121506A1 (es) * | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| FR2918061B1 (fr) | 2007-06-28 | 2010-10-22 | Sanofi Aventis | Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique. |
| WO2009047163A1 (en) | 2007-10-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| CN102574843B (zh) * | 2009-10-22 | 2015-06-17 | 法博太科制药有限公司 | 抗纤维化剂的稠环类似物 |
| EA029718B1 (ru) * | 2012-06-27 | 2018-05-31 | 4-Эс-Си Дискавери Гмбх | Бифтордиоксалан-аминобензимидазольные ингибиторы киназы для лечения рака, аутоиммунного воспаления и нарушений цнс |
-
2013
- 2013-06-27 EA EA201500050A patent/EA029718B1/ru not_active IP Right Cessation
- 2013-06-27 EP EP13731822.6A patent/EP2867237A1/en not_active Withdrawn
- 2013-06-27 HK HK15105006.4A patent/HK1204474A1/xx unknown
- 2013-06-27 AU AU2013283318A patent/AU2013283318B2/en not_active Ceased
- 2013-06-27 IN IN2562MUN2014 patent/IN2014MN02562A/en unknown
- 2013-06-27 US US14/411,795 patent/US9580438B2/en not_active Expired - Fee Related
- 2013-06-27 CA CA2877589A patent/CA2877589C/en not_active Expired - Fee Related
- 2013-06-27 WO PCT/EP2013/063537 patent/WO2014001464A1/en not_active Ceased
- 2013-06-27 NZ NZ702618A patent/NZ702618A/en not_active IP Right Cessation
- 2013-06-27 MX MX2014015938A patent/MX350418B/es active IP Right Grant
- 2013-06-27 UA UAA201500560A patent/UA116541C2/uk unknown
- 2013-06-27 KR KR1020157001782A patent/KR102155559B1/ko not_active Expired - Fee Related
- 2013-06-27 JP JP2015519098A patent/JP6272846B2/ja not_active Expired - Fee Related
- 2013-06-27 MY MYPI2014003556A patent/MY167785A/en unknown
- 2013-06-27 SG SG11201408617PA patent/SG11201408617PA/en unknown
- 2013-06-27 BR BR112014032581A patent/BR112014032581A8/pt not_active Application Discontinuation
- 2013-06-27 CN CN201380034461.4A patent/CN104540831B/zh not_active Expired - Fee Related
-
2014
- 2014-12-12 ZA ZA2014/09194A patent/ZA201409194B/en unknown
- 2014-12-25 IL IL236463A patent/IL236463A0/en unknown
-
2017
- 2017-02-27 US US15/443,180 patent/US20170240556A1/en not_active Abandoned
-
2018
- 2018-01-04 JP JP2018000285A patent/JP2018076360A/ja active Pending
- 2018-02-22 AU AU2018201275A patent/AU2018201275A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR102155559B1 (ko) | 2020-09-15 |
| MY167785A (en) | 2018-09-25 |
| CN104540831A (zh) | 2015-04-22 |
| MX2014015938A (es) | 2015-07-21 |
| BR112014032581A8 (pt) | 2018-08-14 |
| EP2867237A1 (en) | 2015-05-06 |
| JP2018076360A (ja) | 2018-05-17 |
| BR112014032581A2 (pt) | 2017-06-27 |
| CN104540831B (zh) | 2017-11-07 |
| ZA201409194B (en) | 2017-08-30 |
| EA201500050A1 (ru) | 2015-09-30 |
| AU2018201275A1 (en) | 2018-03-15 |
| CA2877589C (en) | 2019-11-26 |
| IN2014MN02562A (OSRAM) | 2015-07-24 |
| JP2015525742A (ja) | 2015-09-07 |
| WO2014001464A1 (en) | 2014-01-03 |
| IL236463A0 (en) | 2015-02-26 |
| MX350418B (es) | 2017-09-06 |
| US20170240556A1 (en) | 2017-08-24 |
| AU2013283318B2 (en) | 2017-11-23 |
| NZ702618A (en) | 2016-12-23 |
| HK1204474A1 (en) | 2015-11-20 |
| AU2013283318A1 (en) | 2015-01-22 |
| EA029718B1 (ru) | 2018-05-31 |
| JP6272846B2 (ja) | 2018-01-31 |
| CA2877589A1 (en) | 2014-01-03 |
| US20150158878A1 (en) | 2015-06-11 |
| US9580438B2 (en) | 2017-02-28 |
| SG11201408617PA (en) | 2015-01-29 |
| KR20150037877A (ko) | 2015-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA116541C2 (uk) | Біфтордіоксаланамінобензімідазольні інгібітори кінази для лікування злоякісного новоутворення, аутоімунного запалення і порушень цнс | |
| US12365653B2 (en) | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof | |
| JP6759514B2 (ja) | ブロモドメインに対して活性な化合物 | |
| US10604532B2 (en) | Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseases | |
| TWI382024B (zh) | 新穎之吡啶酮及嗒酮 | |
| CN113214287B (zh) | Hpk1抑制剂及其使用方法 | |
| JP5836367B2 (ja) | Ａｔｒキナーゼ阻害剤として有用な化合物 | |
| RU2559895C2 (ru) | Азотосодержащие производные гетероарилов | |
| JP2014141529A (ja) | キナーゼのインヒビターとして有用なチアゾールおよびピラゾール | |
| WO2006085685A1 (ja) | ピラゾール化合物 | |
| UA110324C2 (en) | Jak inhibitory compounds based on pyrazolo pyrimidine | |
| JP2013231083A (ja) | キナーゼ阻害剤として有用なチアゾールおよびピラゾール | |
| CA2839743A1 (en) | Trpv4 antagonists | |
| AU2008247595A1 (en) | Aminopyrimidines useful as kinase inhibitors | |
| WO2005014576A1 (ja) | イソキノリノン誘導体、その製造法および用途 | |
| JP2003119191A (ja) | ベンゾアゼピン誘導体、その製造法および用途 | |
| JP2022521895A (ja) | ファルネソイドｘ受容体モジュレータとしての置換二環式化合物 |